Oral tongue squamous cell carcinoma is on the rise in young caucasian females, age 18 to 44 years

Source: Journal of Clinical Oncology   Abstract Purpose To evaluate the incidence of oral cavity squamous cell carcinoma (OCSCC) and oral tongue squamous cell carcinoma (OTSCC) in young white women, age 18 to 44 years. Patients and Methods We analyzed incidence and survival data from the Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute from 1975 to 2007 for OCSCC and OTSCC. Three cohorts were examined: all ages, age 18 to 44 years (ie, “young”), and age > 44 years. Individuals were stratified by sex and/or race. Percentage change (PC) and annual percentage change (APC) were calculated. Joinpoint regression analyses were performed to examine trend differences. Results Overall, incidence of OCSCC was decreasing for all ages. However, incidence was increasing for young white women (PC, 34.8; APC, 2.2; P < .05). Incidence of OTSCC was decreasing for all ages except in the age 18 to 44 years group (PC, 28.8; APC, 1.8; P < .05). Young white individuals had increasing incidence trends of OTSCC (white women: PC, 111.3; APC, 4; P < .05; young white men: PC, 43.7; APC, 1.6; P < .05). The APC of OTSCC was significantly greater in young white women compared with that in young white men (P = .007). Furthermore, incidence of SCC in all other subsites of the oral cavity was decreasing. Nonwhites had a decreasing incidence of OCSCC and OTSCC. Cause-specific survival was similar among whites age 18 to 44 and individuals older than age 44 years. Conclusion OTSCC [...]

2011-04-10T17:26:36-07:00April, 2011|Oral Cancer News|

Dental professionals join The Oral Cancer Foundation to raise awareness as HPV is now the primary cause of Oral Cancers in America

NEWPORT BEACH, Calif., April 4, 2011 /PRNewswire/ -- A serious change in the cause of oral cancer is taking place nationally, and its implications are impacting the American public in a manner that a decade ago no one would have predicted. For decades, oral cancer (also known as mouth cancer, tongue cancer, tonsil cancer, and throat cancer) has been a disease which most often occurred in older individuals, who during their lifetimes had been tobacco users.  Most cases were ultimately the result of lifestyle choices. Today that paradigm has changed. A common, sexually transferred virus has replaced tobacco as the number one cause of oral cancers, Human Papilloma Virus number 16 (HPV16). This is one of the same viruses that are responsible for the majority of cervical cancers in women. This year alone, approximately 37,000 Americans will be newly diagnosed with oral cancer, and one person will die every hour of every day from this disease. HPV16, one of about 130 versions of the virus, is now the leading cause of oral cancer, and is found in about 60% of newly diagnosed patients. Dr. Maura Gillison from the James Cancer Center, a long time researcher of the relationship between HPV and oral cancers, recently reported these new findings at the American Academy for the Advancement of Science meeting. This change in etiology, which has accelerated its influence over the last two decades as tobacco use in the US simultaneously was declining, has also changed the demographics of who is getting [...]

2011-04-07T10:39:32-07:00April, 2011|OCF In The News, Oral Cancer News|

Patient who loses jaw to oral cancer from smoking tells her story

Source: Los Angeles Times By: Milton D. Carrero, The Morning Call   Look at Christine Brader's deep, amber eyes and you will see her beauty. Look beyond her contorted lips, and the jaw she lost as a three-time oral cancer survivor. Radiation took away her teeth, but she smiles. "I still feel like I've lost a great deal, she says, "but I'm still alive. And as long as I am alive, I am going to do what I can to help other people." Brader, 48, is sharing her face, her story and her time to tell the world about the dangers of smoking. The South Whitehall woman, who smoked about half-a-pack a day for 28 years, is featured in the national Truth campaign. Sponsored by the American Legacy Foundation, the series of ads present the unsweetened reality of those living with a serious illness caused by smoking. Brader's life is testament of resilience against oral cancer — a disease that, in five years, kills more than half of the 37,000 Americans diagnosed with it yearly, according to the Oral Cancer Foundation. "I still may not make it," she says, "and I don't have another chance in me. If I get it again, I'm done." Brader's life seemed idyllic until she discovered she had cancer. She had a stable job, a beautiful house in the woods and two teenage children who inspired her. But in 2007, she went to her family doctor, believing that she had a sinus infection. Her situation [...]

2017-03-29T19:08:10-07:00April, 2011|OCF In The News, Oral Cancer News|

Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection

Journal of the National Cancer Institute, April 5, 2011. Authors: Ana Cecilia Rodríguez, Mark Schiffman, Rolando Herrero, Allan Hildesheim, Concepción Bratti, Mark E. Sherman, Diane Solomon, Diego Guillén, Mario Alfaro, Jorge Morales, Martha Hutchinson, Hormuzd Katki, Li Cheung, Sholom Wacholder, Robert D. Burk Background The natural history of human papillomavirus (HPV) infections in older women is critical for preventive strategies, including vaccination and screening intervals, but is poorly understood. In a 7-year population-based cohort study in Guanacaste, Costa Rica, we examined whether women’s age and the duration of carcinogenic HPV infections influenced subsequent persistence of infection and risk of cervical intraepithelial neoplasia grade 2 (CIN 2) or worse disease. Methods At enrollment, of the 9466 participants eligible for pelvic examination, 9175 were screened for cervical neoplasia using multiple methods; those with CIN 2 or worse disease were censored and treated. Participants at low risk of CIN 2 or worse (n = 6029) were rescreened at 5–7 years (passively followed), whereas higher-risk participants (n = 2115) and subsets of low-risk women (n = 540) and initially sexually inactive women (n = 410) were rescreened annually or semiannually (actively followed) for up to 7 years. HPV testing was done using a polymerase chain reaction–based method. We determined, by four age groups (18–25, 26–33, 34–41, and ≥42 years), the proportion of prevalent infections (found at baseline) and newly detected infections (first found during follow-up) that persisted at successive 1-year time points and calculated absolute risks of CIN 2 and CIN grade 3 (CIN [...]

2011-04-10T17:25:47-07:00April, 2011|Oral Cancer News|

HPV link comes as a shock to male cancer patients

By ANIKA CLARK Stanley Sikora of Fall River and Tom Souza of Swansea clearly remember when they started their battles with cancer — life-changing moments while raking leaves or shaving, when they touched their necks and felt a lump. It's a common experience thanks to a disease that, between the suffering of friends, families and ourselves, has become nearly universal. But then came news neither expected. Tumors from both men tested positive for human papillomavirus, an often sexually transmitted virus that is increasingly being linked to cancers of the head and neck. At Massachusetts General Hospital's Center for Head and Neck Cancers, "it's something that we see practically on a daily basis," said Dr. Lori Wirth, medical director for head and neck oncology, who said in an email that, although there are not-fully-understood co-factors, there's strong data that about 60-65 percent of all cancers of the oropharynx (the rear of the mouth, including the back of the throat, tonsils and the base of the tongue) are HPV-related. "Our awareness that HPV is associated with oropharynx cancers is something that has been emerging over the last 5-10 years," she said. "Ten years ago, we didn't even look for (it)." Upon learning of his HPV diagnosis, "I honestly felt creepy about myself," said Sikora, 59, albeit somewhat reassured when he found out how easily it's transmitted. "Already I was shocked that I got cancer. Now it's from HPV," he said. "So I'm thinking 'I can't be going around telling people I got [...]

We owe it to our sons to protect them against human papilloma virus – the new oral cancer peril

The seemingly unstoppable rise of throat and mouth cancers over the past two decades has left experts baffled and deeply concerned. These are truly horrible diseases. More than 15,000 new patients are diagnosed each year in Britain alone and almost 8,000 die from the most common type, cancer of the oesophagus. Two-thirds of sufferers are men. And those that survive are often left horrifically disfigured by aggressive radiotherapy and surgery. Most worryingly, numbers of new cases have doubled since 1989. We used to think most oral and throat cancers  -  which also include laryngeal (voice box), tracheal (windpipe) and oropharyngeal (soft-palate) tumours  -  were due to a lifetime of smoking and heavy alcohol consumption, and only really occurred in old age. But as health messages hit home, numbers of smokers and drinkers dropped, fewer older men and women developed these cancers and a new group of patients  -  middle-class, middle-aged men who drank moderately and had never smoked  -  emerged. This was a surprise. Small studies, in which tumours were analysed, indicated a new culprit: the human papilloma virus (HPV), the same virus that we knew was the cause of cervical cancer in women. For years there have been whisperings among oncologists that this could become one of the most significant cancer challenges of the 21st Century. And six weeks ago, evidence published by two American universities showed that these fears were becoming a reality. Researchers found that about half of the male population carried some form of HPV; that every year [...]

HPV type-specific prevalence using a urine assay in unvaccinated male and female 11- to 18-year olds in Scotland

Source: British Journal of Cancer Background: We conducted a baseline prevalence survey of unvaccinated 11- to 18-year olds to inform effectiveness studies for the new human papillomavirus (HPV) immunisation programme in Scotland. Methods: Participants were recruited from schools and colleges and invited to provide demographic data and an anonymous urine sample for type-specific HPV testing. Results: Among females aged 11–14 years, the weighted prevalence was 1.1% overall; 0.9% for high-risk types and no infections were associated with types 16 and 18. Among 15- to 18-year old females, the weighted prevalence was 15.2% overall; 12.6% for high-risk types and 6.5% for types 16 and 18. Among females aged 16–18 years, infection was more frequently associated with attending college and rural schools, and showed a trend towards increasing prevalence with increasing social deprivation (P=0.045). Among males aged 11–14 years, the weighted prevalence was 1.4% overall; 1.0% for high-risk types and 0.7% for types 16 and 18. Among 15- to 18-year old males, the weighted prevalence was 3.9% overall; 2.4% for high-risk types and 0.7% for types 16 and 18. Conclusions: Human Papillomavirus prevalence is low among 11- to 14-year olds, which includes the age group targeted for routine vaccination. The prevalence in males and correlation with deprivation require further investigation.

Study Finds Few Second Cancers Attributable to Radiotherapy

Elsevier Global Medical News Author: MA Moon It appears that only 8% of second solid cancers can be attributed to radiotherapy for a first cancer, according to a report published online March 30 in the Lancet. This figure varies somewhat according to the site of the first solid tumor, with the lowest attributable risk (4%) in cancers of the eye or orbit and the highest attributable risk (24%) in cancers of the testes. Given that only a small proportion of second cancers among adult survivors are likely to be related to radiotherapy, it follows that most second cancers arise from other causes, such as genetics or lifestyle factors, said Amy Berrington de Gonzalez, D.Phil., of the National Cancer Institute, and her associates. "These findings can be used by physicians and patients to put the risk of radiation-related cancer into perspective when compared with the probable benefits of treatment," the researchers noted. Many studies have shown an association between receiving radiotherapy for a first solid tumor and subsequently developing a second solid tumor. However, the proportion of second cancers that might be related to radiotherapy has not been investigated before, they said. Dr. Berrington de Gonzalez and her colleagues used data from the U.S. SEER (Surveillance, Epidemiology, and End Results) cancer registry to perform "a comprehensive and systematic analysis of all first solid cancer sites in adults that are routinely treated with radiotherapy." They included 647,672 patients who were 5-year cancer survivors and were aged 20 years and older when they were diagnosed with a first primary invasive solid cancer in 1973-2002. The participants were followed for 5-34 years (mean follow-up, [...]

Vandetanib Restores Head and Neck Squamous Cell Carcinoma Cells’ Sensitivity to Cisplatin and Radiation In Vivo and In Vitro

Abstract Purpose: We investigated whether vandetanib, an inhibitor of the tyrosine kinase activities of vascular endothelial growth factor receptor-2 (VEGFR-2), epidermal growth factor receptor (EGFR), and rearranged during transfection (RET), could augment the antitumor activity of radiation with or without cisplatin in preclinical in vitro and in vivo models of human head and neck squamous cell carcinoma (HNSCC). Experimental Design: OSC-19 and HN5 HNSCC cells that were cisplatin and radioresistant were treated with vandetanib, cisplatin, and radiation alone or in combination in vitro and in vivo using an orthotopic nude mouse model. Treatment effects were assessed using clonogenic survival assay, tumor volume, bioluminescence imaging, tumor growth delay, survival, microvessel density, tumor and endothelial cell apoptosis, and EGFR and Akt phosphorylation data. Results: Vandetanib plus cisplatin radiosensitized HNSCC cells in vitro and in vivo. The combination treatment with vandetanib, cisplatin, and radiation was superior to the rest of treatments (including the double combinations) in antitumoral effects, prolonging survival, decreasing cervical lymph node metastases in vivo. It also increased both tumor and tumor-associated endothelial cell apoptosis and decreased microvessel density in vivo. An analysis of tumor growth delay data revealed that vandetanib plus cisplatin enhanced radioresponse in vivo. All vandetanib-containing treatments inhibited EGFR and Akt phosphorylation in vitro and in vivo. Conclusion: The addition of vandetanib to combination therapy with cisplatin and radiation was able to effectively overcome cisplatin and radioresistance in in vitro and in vivo models of HNSCC. Further study of this regimen in clinical trials may be warranted. Clin [...]

Multivitamins Don’t Lower Cancer and Cardiovascular Risk

Source: MedScape Today By: Leigh Krietsch Boerner Will taking multivitamins protect you from dying of cancer or cardiovascular disease? The answer is no, according to new research published online February 22 in the American Journal of Epidemiology. In a study of more than 180,000 people, researchers saw the same number of deaths from cancer and heart disease among multivitamin-takers and those who didn't take the supplements. "People need to understand that just taking these multivitamins is not sufficient to prevent disease," said Dr. Jennifer Hsiang-Ling Lin, of Brigham and Women's Hospital in Boston, who didn't work on the study. Multiple past studies have shown no link between multivitamins and reduced risk of cancer or heart disease. Other recent research couldn't prove that multivitamins protect against diabetes, either. Some small studies in the past have shown that specific vitamins, not multivitamins, may be protective against heart disease or cancer later in life. However these studies looked at undernourished people, not generally healthy adults like the U.S. population, said co-author Dr. Song-Yi Park of the University of Hawaii Cancer Center in Honolulu. On its web site, the U.S. National Institutes of Health advises that doctors should prescribe multivitamins only "for patients who need extra vitamins, who cannot eat enough food to obtain the required vitamins, or who cannot receive the full benefit of the vitamins contained in the food they eat." But more than half of U.S. adults choose to take multivitamins, according to Dr. Lin. Altogether, Dr. Park's team looked at [...]

Go to Top